ANGPTL3

Angiopoietin-like 3
Identifiers
Symbols ANGPTL3 ; ANG-5; ANGPT5; ANL3; FHBL2
External IDs OMIM: 604774 MGI: 1353627 HomoloGene: 8499 GeneCards: ANGPTL3 Gene
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez 27329 30924
Ensembl ENSG00000132855 ENSMUSG00000028553
UniProt Q9Y5C1 Q9R182
RefSeq (mRNA) NM_014495 NM_013913
RefSeq (protein) NP_055310 NP_038941
Location (UCSC) Chr 1:
62.6 – 62.61 Mb		 Chr 4:
99.03 – 99.05 Mb
PubMed search

Angiopoietin-like 3, also known as ANGPTL3, is a protein that in humans is encoded by the ANGPTL3 gene.[1][2]

Function

The protein encoded by this gene is a member of the angiopoietin-like family of secreted factors. It is expressed predominantly in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain, and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis.[1]

Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibits endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-rich HDL particles have high cholesterol efflux abilities.

Angptl3 plays a major role in promoting uptake of circulating triglycerides into white adipose tissue in the fed state,[3] likely through activation by Angptl8, a feeding-induced hepatokine,[4][5] to inhibit postprandial LPL activity in cardiac and skeletal muscles,[6] as suggested by the ANGPTL3-4-8 model.[7]

Clinical significance

In human, ANGPTL3 is a determinant factor of HDL level and positively correlates with plasma HDL cholesterol.

In humans with genetic loss-of-function variants in one copy of ANGPTL3, the serum LDL-C levels are reduced. In those with loss-of-function variants in both copies of ANGPTL3, low LDL-C, low HDL-C, and low triglycerides are seen ("familial combined hypolipidemia").[8]

References

  1. 1 2 "Entrez Gene: ANGPTL3 angiopoietin-like 3".
  2. ↑ Conklin D, Gilbertson D, Taft DW, Maurer MF, Whitmore TE, Smith DL, Walker KM, Chen LH, Wattler S, Nehls M, Lewis KB (December 1999). "Identification of a mammalian angiopoietin-related protein expressed specifically in liver". Genomics 62 (3): 477–82. doi:10.1006/geno.1999.6041. PMID 10644446.
  3. ↑ Wang Y, McNutt MC, Banfi S, Levin MG, Holland WL, Gusarova V, Gromada J, Cohen JC, Hobbs HH (Sep 2015). "Hepatic ANGPTL3 regulates adipose tissue energy homeostasis". Proceedings of the National Academy of Sciences of the United States of America 112 (37): 11630–5. doi:10.1073/pnas.1515374112. PMID 26305978.
  4. ↑ Zhang R (Aug 2012). "Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels". Biochemical and Biophysical Research Communications 424 (4): 786–92. doi:10.1016/j.bbrc.2012.07.038. PMID 22809513.
  5. ↑ Ren G, Kim JY, Smas CM (Aug 2012). "Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism". American Journal of Physiology. Endocrinology and Metabolism 303 (3): E334–51. doi:10.1152/ajpendo.00084.2012. PMID 22569073.
  6. ↑ Fu Z, Abou-Samra AB, Zhang R (December 2015). "A lipasin/Angptl8 monoclonal antibody lowers mouse serum triglycerides involving increased postprandial activity of the cardiac lipoprotein lipase". Scientific Reports 5: 18502. doi:10.1038/srep18502. PMID 26687026.
  7. ↑ Zhang R (April 2016). "The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking.". Open Biology 6: 150272. doi:10.1098/rsob.150272. PMID 27053679.
  8. ↑ Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, Garimella KV, Fisher S, Abreu J; et al. (2010). "Exome Sequencing,ANGPTL3Mutations, and Familial Combined Hypolipidemia". New England Journal of Medicine 363 (23): 2220–2227. doi:10.1056/NEJMoa1002926. PMC: 3008575. PMID 20942659.

Further reading

  • Miida T, Seino U, Miyazaki O, Hanyu O, Hirayama S, Saito T, Ishikawa Y, Akamatsu S, Nakano T, Nakajima K, Okazaki M, Okada M (October 2008). "Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling". Atherosclerosis 200 (2): 329–35. doi:10.1016/j.atherosclerosis.2007.12.031. PMID 18279878. 
  • Moon HD, Nakajima K, Kamiyama K, Takanashi K, Sakurabayashi I, Nagamine T (December 2008). "Higher frequency of abnormal serum angiopoietin-like protein 3 than abnormal cholesteryl ester transfer protein in Japanese hyperalphalipoproteinemic subjects". Clin. Chim. Acta 398 (1–2): 99–104. doi:10.1016/j.cca.2008.08.021. PMID 18804459. 
  • Li C (2007). "Genetics and regulation of angiopoietin-like proteins 3 and 4". Curr. Opin. Lipidol. 17 (2): 152–6. doi:10.1097/01.mol.0000217896.67444.05. PMID 16531751. 
  • Camenisch G, Pisabarro MT, Sherman D; et al. (2002). "ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo". J. Biol. Chem. 277 (19): 17281–90. doi:10.1074/jbc.M109768200. PMID 11877390. 
  • Strausberg RL, Feingold EA, Grouse LH; et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC: 139241. PMID 12477932. 
  • Kaplan R, Zhang T, Hernandez M; et al. (2003). "Regulation of the angiopoietin-like protein 3 gene by LXR". J. Lipid Res. 44 (1): 136–43. doi:10.1194/jlr.M200367-JLR200. PMID 12518032. 
  • Shimamura M, Matsuda M, Kobayashi S; et al. (2003). "Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes". Biochem. Biophys. Res. Commun. 301 (2): 604–9. doi:10.1016/S0006-291X(02)03058-9. PMID 12565906. 
  • Zeng L, Dai J, Ying K; et al. (2003). "Identification of a novel human angiopoietin-like gene expressed mainly in heart". J. Hum. Genet. 48 (3): 159–62. doi:10.1007/s100380300025. PMID 12624729. 
  • Ono M, Shimizugawa T, Shimamura M; et al. (2004). "Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo". J. Biol. Chem. 278 (43): 41804–9. doi:10.1074/jbc.M302861200. PMID 12909640. 
  • Clark HF, Gurney AL, Abaya E; et al. (2003). "The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment". Genome Res. 13 (10): 2265–70. doi:10.1101/gr.1293003. PMC: 403697. PMID 12975309. 
  • Zhang Z, Henzel WJ (2005). "Signal peptide prediction based on analysis of experimentally verified cleavage sites". Protein Sci. 13 (10): 2819–24. doi:10.1110/ps.04682504. PMC: 2286551. PMID 15340161. 
  • Gerhard DS, Wagner L, Feingold EA; et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC: 528928. PMID 15489334. 
  • Liu T, Qian WJ, Gritsenko MA; et al. (2006). "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry". J. Proteome Res. 4 (6): 2070–80. doi:10.1021/pr0502065. PMC: 1850943. PMID 16335952. 
  • Shimamura M, Matsuda M, Yasumo H; et al. (2007). "Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase". Arterioscler. Thromb. Vasc. Biol. 27 (2): 366–72. doi:10.1161/01.ATV.0000252827.51626.89. PMID 17110602. 


This article is issued from Wikipedia - version of the Sunday, April 17, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.